Background: There is conflicting literature regarding the association of the BRAF V600E
mutation and aggressive clinicopathological features of papillary thyroid cancer (PTC) …

Background The objective of this study is to perform a meta-analysis to evaluate the
associations between the BRAF V600E mutation status and aggressive clinicopathological …

BACKGROUND. Numerous studies have investigated the clinical significance of BRAF
mutation in papillary thyroid carcinoma (PTC). However, there have been conflicting data on …

BACKGROUND: The effects of the BRAFV600E mutation on prognostic factors and poor
clinical outcomes in papillary thyroid cancer (PTC) have not been fully quantified. The …

Abstract Background The BRAF V600E mutation is the most common genetic alteration
found in papillary thyroid cancer (PTC). Recent studies show that this mutation occurs more …

Abstract Background/Aims: The function of BRAF V600E as a prognostic biomarker
continues controversial by reason of conflicting results in the published articles. Methods: A …

Importance Papillary thyroid carcinoma (PTC) is the most common endocrine neoplasm. B-
type raf kinase (BRAF) V600E mutation has been proposed as a negative prognostic …

Context: Because very few studies have examined the correlation between BRAF mutations
and clinicopathological features of papillary thyroid carcinoma (PTC), we analyzed here a …

Context: Evaluation of the degree of neoplastic infiltration beyond the thyroid capsule
remains a unique parameter that can be evaluated by histopathological examination to label …

Background: The BRAF mutation has been shown to be associated with aggressive
clinicopathologic characteristics of papillary thyroid cancer (PTC). However, several studies …